A mathematical model for cisplatin cellular pharmacodynamics

Ardith W El-Kareh1, Timothy W Secomb

  • 1ARL-Microcirculation Division, University of Arizona, Tucson, AZ 85724-5051, USA. elkareh@u.arizona.edu

Neoplasia (New York, N.Y.)
|March 28, 2003
PubMed

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...
Pharmacodynamic Models: Emax Drug–Concentration Effect Model01:18

Pharmacodynamic Models: Emax Drug–Concentration Effect Model

The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...